vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $18.6M, roughly 1.4× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -49.7%, a 115.4% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 13.1%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 1.8%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
BCBP vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $18.6M |
| Net Profit | $-12.0M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -71.9% | 56.3% |
| Net Margin | -49.7% | 65.7% |
| Revenue YoY | 13.1% | 1808.5% |
| Net Profit YoY | -467.6% | 376.5% |
| EPS (diluted) | $-0.73 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $18.6M | ||
| Q3 25 | $26.5M | $334.0K | ||
| Q2 25 | $25.2M | $1.4M | ||
| Q1 25 | $23.8M | $257.0K | ||
| Q4 24 | $23.1M | $977.0K | ||
| Q3 24 | $26.2M | $660.0K | ||
| Q2 24 | $20.4M | $736.0K | ||
| Q1 24 | $25.3M | $1.4M |
| Q4 25 | $-12.0M | $12.3M | ||
| Q3 25 | $4.3M | $-8.6M | ||
| Q2 25 | $3.6M | $-6.9M | ||
| Q1 25 | $-8.3M | $-5.4M | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $6.7M | $-2.8M | ||
| Q2 24 | $2.8M | $-14.5M | ||
| Q1 24 | $5.9M | $411.0K |
| Q4 25 | -71.9% | 56.3% | ||
| Q3 25 | 21.9% | -2516.5% | ||
| Q2 25 | 19.9% | -701.0% | ||
| Q1 25 | -49.2% | -3350.2% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 35.7% | -1563.6% | ||
| Q2 24 | 19.5% | -1255.0% | ||
| Q1 24 | 33.0% | -692.5% |
| Q4 25 | -49.7% | 65.7% | ||
| Q3 25 | 16.1% | -2572.2% | ||
| Q2 25 | 14.2% | -504.8% | ||
| Q1 25 | -35.0% | -2097.7% | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 25.5% | -425.5% | ||
| Q2 24 | 13.8% | -1964.4% | ||
| Q1 24 | 23.2% | 29.9% |
| Q4 25 | $-0.73 | $0.25 | ||
| Q3 25 | $0.22 | $-0.17 | ||
| Q2 25 | $0.18 | $-0.14 | ||
| Q1 25 | $-0.51 | $-0.11 | ||
| Q4 24 | $0.17 | — | ||
| Q3 24 | $0.36 | $-0.06 | ||
| Q2 24 | $0.14 | $-0.30 | ||
| Q1 24 | $0.32 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $49.4M |
| Total Assets | $3.3B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $304.3M | $49.4M | ||
| Q3 25 | $318.5M | $36.4M | ||
| Q2 25 | $315.7M | $44.5M | ||
| Q1 25 | $314.7M | $50.5M | ||
| Q4 24 | $323.9M | $55.1M | ||
| Q3 24 | $328.1M | $58.5M | ||
| Q2 24 | $320.7M | $60.4M | ||
| Q1 24 | $320.1M | $74.1M |
| Q4 25 | $3.3B | $59.0M | ||
| Q3 25 | $3.4B | $51.1M | ||
| Q2 25 | $3.4B | $60.7M | ||
| Q1 25 | $3.5B | $67.9M | ||
| Q4 24 | $3.6B | $90.6M | ||
| Q3 24 | $3.6B | $99.0M | ||
| Q2 24 | $3.8B | $107.8M | ||
| Q1 24 | $3.8B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $18.4M |
| Free Cash FlowOCF − Capex | $34.9M | — |
| FCF MarginFCF / Revenue | 133.3% | — |
| Capex IntensityCapex / Revenue | 4.0% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $18.4M | ||
| Q3 25 | $8.7M | $-8.7M | ||
| Q2 25 | $10.3M | $-7.5M | ||
| Q1 25 | $5.0M | $-7.5M | ||
| Q4 24 | $67.7M | $-24.0M | ||
| Q3 24 | $43.5M | $765.0K | ||
| Q2 24 | $8.1M | $-10.9M | ||
| Q1 24 | $8.3M | $-4.0M |
| Q4 25 | $34.9M | — | ||
| Q3 25 | $8.5M | — | ||
| Q2 25 | $10.2M | — | ||
| Q1 25 | $4.7M | — | ||
| Q4 24 | $66.5M | — | ||
| Q3 24 | $43.4M | — | ||
| Q2 24 | $8.1M | — | ||
| Q1 24 | $8.1M | — |
| Q4 25 | 133.3% | — | ||
| Q3 25 | 32.0% | — | ||
| Q2 25 | 40.4% | — | ||
| Q1 25 | 19.8% | — | ||
| Q4 24 | 287.5% | — | ||
| Q3 24 | 166.0% | — | ||
| Q2 24 | 39.6% | — | ||
| Q1 24 | 32.3% | — |
| Q4 25 | 4.0% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCBP
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
